AP C5 |
| Katalog-Nr.GC50527 |
AP C5 zeigt eine selektive Hemmung der Guanosin-3′,5′-cyclischen Monophosphat (cGMP)-abhängigen Proteinkinase II (cGKII) mit einem pIC50 von 7,2, was für die Erforschung von Durchfallerkrankungen verwendet werden kann.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2234272-10-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Potent and selective protein kinase G type II (PKG2) inhibitor (pIC50 = 7.2). Displays >20-fold selectivity for PKG2 over PKG1 and PKA (pIC50 values are 4.6 and 4.8 for PKG1 and PKA, respectively). Blocks 8-pCPT-cGMP-dependent VASP phosphorylation in intestinal organoids. Also attenuates toxin-stimulated anion secretory responses in mouse intestinal tissue.
Bijvelds et al (2018) Selective inhibition of intestinal guanosine 3',5'-cyclic monophosphate signaling by small-molecule protein kinase inhibitors. J.Biol.Chem. 293 8173 PMID:29653944
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *